Neuron and Axon Regeneration in Cases of Glial Scarring in Chronic Neurodegeneration

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases with a combination of ground-breaking technology and biology, with an extensive track record of academic collaboration. They are seeking a solution that achieves neuron regeneration or axon regeneration within glial scarring in animal models.

Regeneration within glial scarring caused by the following diseases are of interest to the client:

- Stroke
- Spinal cord injury
- Traumatic brain injury
- Parkinson's disease
- Charcot-Marie-Tooth disease
- Huntington disease
- Peripheral nerve injury, in chronic stage (not acute phase)
- Amyotrophic Lateral Sclerosis

They are also seeking functional motor recovery of animal models with these targets. All modalities with these targets will be considered, such as:

- Adeno-associated virus
- Nucleic acid, protein, antibody, bio-materials, or small compound

Out of Scope:

- Cell therapy projects (i.e. replenishment with in vitro reprogrammed cells)
- Alzheimer's Disease and Dementia are not of interest
- Non-mammalian animal models are not within scope

Stage of Development:

Pre-clinical and late pre-clinical solutions will be considered.

Submission Information:

Submission of one-page summaries of Research Projects, Technology Briefs, Academic Profiles, Centres of Excellence and Spin-Outs are encouraged. Alternatively, please fill out an application form available here.

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 7th December 2020 - 11:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

© 2020 IN-PART All rights reserved